|Bid||1.0000 x 36100|
|Ask||1.0100 x 4000|
|Day's Range||1.0000 - 1.0400|
|52 Week Range||0.4700 - 2.5500|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 12, 1980|
|1y Target Est||N/A|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021. The poster presentation of the data was by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. The full presentation is available at: https://conferences.asco.org
New York, New York--(Newsfile Corp. - May 20, 2021) - PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals (NASDAQ: AIKI), according to the company's Q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide therapy (PRRT) with notable insider buying in the open market displaying his strong belief in the Company's prospects.Developed by Weill Cornell ...